Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payments ...

Genzyme (Cambridge, MA) acquired Cell Genesys (Foster City, CA), a firm with a large patent estate for gene therapy, clinical-stage cancer drugs, and novel gene activation technology, in October ...

Fact checked by Katrina Munichiello Reviewed by Somer Anderson What Is a Hostile Takeover? A hostile takeover happens when an acquiring company moves forward with buying another company, the target ...

Genzyme continued to drive growth for Sanofi in the first quarter, helped along by the company’s vaccines unit, but diabetes drugs are still struggling. Net sales were €8,391 million ...

The company remains convinced of the product's merits and—bolstered by the backing of a $1.38 billion deal from Genzyme a year ago—continues to pursue cardiac and other autoimmune indications.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Khanna, Tarun, and Christopher A. Bartlett. "Genzyme's CSR Dilemma: How to Play its HAND - video supplement." Harvard Business School Video Supplement 910-801, January 2010.